Guardant Well being Names Michael Bell as New Chief Money Officer

“I am delighted to welcome Michael Bell to our executive leadership staff,” claimed Helmy Eltoukhy, Guardant Wellbeing CEO. “Michael is a proven company chief whose considerable knowledge top the monetary operations of main medical diagnostic and pharmaceutical corporations will make a incredible influence as we continue to place Guardant Well being for the foreseeable future and progress toward our objective of transforming most cancers treatment throughout all phases of the disease.”

Helmy Eltoukhy provides, “I also desire Derek Bertocci the incredibly ideal as he takes on this future chapter of his existence. I am grateful for his dependable partnership in positioning Guardant Overall health for lengthy-time period progress. On behalf of the company and the Board of Directors, I thank Derek for his management and contributions to Guardant Overall health about the past 4 several years.”

“I’m thrilled to sign up for Guardant Wellness and contribute to the company’s profound mission of conquering most cancers with info,” said Michael Bell. “The business is in a exclusive situation to enable most cancers patients across all stages of the sickness, and I search ahead to doing the job with the unbelievable team at Guardant Well being to continue to scale and support serve even a lot more cancer patients.”

Michael provides above 25 decades of intercontinental finance and accounting expertise to this job just after doing the job in clinical diagnostics, pharma, and public accounting. He was most lately the CFO of CareDx, and was previously the CFO for Metabiota, Singulex, and Novartis Diagnostics. Prior, Michael labored in general public accounting at Ernst & Younger and Deloitte. Michael retains a Bachelor of Science degree in Mathematics with Computing from the University of Leicester in the United Kingdom, and is a Fellow of the Institute of Chartered Accountants in England & Wales.

About Guardant Health

Guardant Health is a main precision oncology firm concentrated on helping conquer most cancers globally as a result of use of its proprietary blood assessments, broad information sets and innovative analytics. The Guardant Wellbeing Oncology Platform leverages abilities to travel commercial adoption, boost individual clinical outcomes and reduce healthcare expenditures across all levels of the most cancers treatment continuum. Guardant Well being has introduced liquid biopsy-based mostly Guardant360^®, Guardant360 CDx and GuardantOMNI^® assessments for innovative stage most cancers sufferers. These assessments gasoline advancement of its LUNAR program, which aims to tackle the needs of early phase cancer individuals with neoadjuvant and adjuvant treatment method range, most cancers survivors with surveillance, asymptomatic individuals suitable for cancer screening and men and women at a greater chance for producing cancer with early detection.

Source: Guardant Health, Inc.

Look at resource model on businesswire.com: https://www.businesswire.com/news/household/20201211005569/en/

Supply: Guardant Wellbeing, Inc.

Investor Call:

Carrie Mendivil

[email protected] Media Get hold of:

Anna Czene

[email protected]

Courtney Carroll

[email protected]

COMTEX_375966614/2456/2020-12-11T17:00:27

Is there a problem with this push release? Make contact with the source supplier Comtex at [email protected]. You can also speak to MarketWatch Buyer Assistance through our Customer Center.

Copyright Small business Wire 2020